News | January 01, 2025
Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
Equity raise to finance growth and investments in the biological space
Subscribe To Our Newsletter & Stay Updated
